Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 2, 2003, Pages 209-215

  Shen, Sui ^a,c   Meredith, Ruby F ^a   Duan, Jun ^a   Brezovich, Ivan ^a   Khazaeli, M B ^b   LoBuglio, Albert F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

Cancer; Dosimetry; Myelotoxicity; Radionuclide therapy

Indexed keywords

MONOCLONAL ANTIBODY CC49 I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BODY MASS; BODY SURFACE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSIMETRY; HUMAN; LEAN BODY WEIGHT; MALE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOACTIVITY; THROMBOCYTE COUNT;

EID: 0038743197     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803765036373     Document Type: Conference Paper

References (20)

1. Siegel JA, Wessels BW, Waston EE, Stabin MG, Vriesendorp HM, Braddley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharmacol 1990; 3: 213-233.
2. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-694.
3. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999; 40: 2102-2106.
4. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B 1989; 16: 553-559.
5. DeNardo SJ, Macey DJ, DeNardo GL. A direct approach for determining marrow radiation from MoAb therapy. American College of Nuclear Physicians, Washington, D.C., 1989; 110-124.
6. Wahl RL, Kroll S, Zasadny KR. Patient-specific wholebody dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39: 14S-20S.
7. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35: 1017-1022.
8. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857.
9. Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med 1991; 32: 1162-1168.
10. Loevinger R, Bermam M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1. Society of Nuclear Medicine New York, 1976.
11. Snyder WS, Ford MR, Warner GG, Watson SB. 'S', Absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. Society of Nuclear Medicine, New York, 1975.
12. Brownell GL, Ellett WH, Reddy AR. Absorbed fractions for photon dosimetry. MIRD Pamphlet No. 3. Society of Nuclear Medicine, New York 1968.
13. Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No.5, revised, Society of Nuclear Medicine, New York; 1978.
14. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-1224.
15. Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 1999; 5: 3243s-3248s.
16. Breitz HB.Dosimetry in myeloablative setting. Cancer Biother Radiopharm 2002; 17: 119-128.
17. Stabin MG. Internal dosimetry in the use of radiopharmaceuticals in therapy - science at a crossroads? Cancer Biother Radiopharm 1999; 14: 81-89.
18. Liu T, Meredith RF, Saleh MN, Wheeler RH, Khazaeli MB, Plott WE, Schlom J, LoBuglio AF. Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm 1997; 12: 79-87.
19. 90Y-antibody therapy. J Nucl Med 2002; 43: 1245-1253.
20. Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 2000; 88: 333-343.